L3VLUP
ProSign in

IART · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IARTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IART
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterIARTVRTX
Q3 20206 holders, $992m31 holders, $21.9bn
Q4 20206 holders, $1.4bn30 holders, $18.4bn
Q1 20214 holders, $1.5bn31 holders, $15.4bn
Q2 20216 holders, $1.5bn30 holders, $12.7bn
Q3 20216 holders, $1.7bn35 holders, $10.1bn
Q4 20216 holders, $1.6bn28 holders, $12.4bn
Q1 20228 holders, $1.3bn23 holders, $16.1bn
Q2 202210 holders, $969m25 holders, $18.1bn
Q3 202214 holders, $702m22 holders, $18.4bn
Q4 202211 holders, $946m28 holders, $18.4bn
Q1 202311 holders, $864m26 holders, $21.4bn
Q2 202312 holders, $492m27 holders, $24.7bn
Q3 202313 holders, $481m33 holders, $24.3bn
Q4 202310 holders, $530m32 holders, $28.6bn
Q1 20248 holders, $378m31 holders, $29.8bn
Q2 20246 holders, $212m29 holders, $33.4bn
Q3 20243 holders, $87m27 holders, $33.5bn
Q4 20243 holders, $60m26 holders, $28.5bn
Q1 20253 holders, $34m21 holders, $35.4bn
Q2 20252 holders, $2.8m21 holders, $32.3bn
Q3 20252 holders, $1.8m22 holders, $25.9bn
Q4 20251 holders, $662k26 holders, $31.8bn
Q1 20261 holders, $679k25 holders, $31.8bn
Q2 20261 holders, $1.8m26 holders, $34.6bn
IART

Integra Lifesciences Holdings Corp

Holders
10
Reported value
$530m
Buyers
5
Sellers
6

Breadth -1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IART (1)

Arrowstreet Capital LP

Only VRTX (23)

Acadian Asset Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Investments LP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →